UK scientists claim DNA repair mystery is solved

30 January 2006

Cancer Research UK scientists believe the final piece of the picture of how cells fix a severe type of DNA damage - thereby reducing the chances that the cells become cancerous - will fall into place tomorrow when they publish their latest findings in the journal Cell on January 27.

Steve Jackson, a professor based at Cambridge University, discovered the first component of one particular DNA repair process over 10 years ago. More pieces were found, and eventually scientists thought they had the whole process mapped out. But recent evidence came to light that suggested there was still one bit missing. Now Prof Jackson has finished what he started by discovering a new molecule that completes the picture.

The molecule is called XLF and, while it may have a role in causing cancer, it can possibly also be targeted by new cancer treatments - for example, blocking the action of XLF in cancer cells could "soften up" the cells and allow radiotherapy to deliver more easily a knockout blow.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight